<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gillis, Anne M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Is it Time for Personalized Medicine in Atrial Fibrillation?</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-10</style></pages><abstract><style  face="normal" font="default" size="100%">The optimal management of patients with atrial fibrillation (AF) is based on multiple patient-centered factors. Emerging research is demonstrating that a broad range of factors including biomarkers and genetics may help to further refine an individual patient's disease characteristics and may in turn help guide therapeutic decision making.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>